Ambrisentan: all 55 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesRecruitingNCT07245680Phase 3
• Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionNot yet recruitingNCT06987097Not applicable
• Comparison of Sequential to Initial Combination Therapy in PAHRecruitingNCT06968962Not applicable
• Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial HypertensionRecruitingNCT04972656Not applicable
• Crossover Study From Macitentan or Bosentan Over to AmbrisentanTerminatedNCT02885012Phase 4Results posted
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)CompletedNCT02290613Phase 2Results posted
• The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension StudyTerminatedNCT02253394Phase 4Results posted
• Ambrisentan in Single VentricleCompletedNCT02080637Phase 2Results posted
• The Effects of Ambrisentan on Exercise Capacity in Fontan PatientsCompletedNCT01971580Phase 4Results posted
• Drug Combination on Exercise Performance at High AltitudeCompletedNCT01902758Phase 2/3Results posted
• A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)TerminatedNCT01894022Phase 3Results posted
• Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.TerminatedNCT01884675Phase 3Results posted
• Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT01808313Phase 3Results posted
• The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy VolunteersCompletedNCT01530464Phase 1Results posted
• Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529CompletedNCT01342952Phase 2Results posted
• An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)CompletedNCT01338636Phase 4Results posted
• Safely Change From Bosentan to Ambrisentan in Pulmonary HypertensionCompletedNCT01330108Phase 4Results posted
• Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label TrialCompletedNCT01224210Phase 3Results posted
• A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT01178073Phase 3Results posted
• Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisCompletedNCT01093885Not applicableResults posted
• Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or FeetCompletedNCT01072669Not applicableResults posted
• Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With AmbrisentanCompletedNCT01051960Phase 4Results posted
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00879229Phase 3Results posted
• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using AmbrisentanTerminatedNCT00840463Phase 4Results posted
• Study of Ambrisentan in Participants With Pulmonary HypertensionCompletedNCT00777920Phase 3Results posted
• (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFTerminatedNCT00768300Phase 3Results posted
• A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).CompletedNCT00725361Not applicableResults posted
• Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)CompletedNCT00617305Phase 4Results posted
• A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)CompletedNCT00578786Phase 3Results posted
• A Study to Evaluate GSK1325760A - a Long-Term Extension StudyCompletedNCT00554619Phase 3Results posted
• Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial HypertensionCompletedNCT00540436Phase 2Results posted
• Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial HypertensionCompletedNCT00424021Phase 2Results posted
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial HypertensionCompletedNCT00423592Phase 2Results posted
• Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary HypertensionCompletedNCT00380068Phase 3Results posted
• Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal SyndromeActive, not recruitingNCT06256432Phase 2
• Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial HypertensionCompletedNCT05437224Phase 3
• A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19TerminatedNCT04771000Phase 2
• Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial HypertensionStatus unknownNCT04528056Phase 1/2
• Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing SurgeryStatus unknownNCT04450095Phase 2
• mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCompletedNCT04393246Phase 2/3
• A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver CirrhosisTerminatedNCT03827200Phase 2
• Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary HypertensionWithdrawnNCT03309592Phase 4
• Mechanisms of Cerebrovascular ControlCompletedNCT02936687Phase 1
• The Role of Endothelin-1 in Sickle Cell DiseaseCompletedNCT02712346Phase 1
• Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial HypertensionTerminatedNCT02169752Not applicable
• A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High AltitudeCompletedNCT01794078Phase 1
• Ambrisentan for Treatment of Portopulmonary HypertensionWithdrawnNCT01733095Phase 1/2
• Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in AsthmaStatus unknownNCT01617746Phase 2
• Characterization and Detection of Prolonged Endothelin Receptors Antagonists AdministrationCompletedNCT01352065Phase 2/3
• Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionCompletedNCT00851929Phase 2/3
• A Study of GSK1325760A in Healthy Japanese SubjectsCompletedNCT00424034Phase 1
• Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.CompletedNCT00423748Phase 3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.CompletedNCT00423202Phase 3
• ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00091598Phase 3
• Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial HypertensionCompletedNCT00046319Phase 2

← Ambrisentan overview